Beijing CC-Pharming is a Beijing-based biotechnology company specializing in the research and development of medical solutions using plant bioreactor technology. Some products that is produces are vaccines, monoclonal antibodies, blood products, and hypoglycemic drugs.
During the COVID-19 pandemic, the company partnered with iBio to produce a medical solution for the virus. Beijing CC-Pharming is set to have developed a product, such as an antibody drug, and iBio is intended to manufacture it.
Dr. Kevin Wang
Creative Approaches Yield Results in the Fight Against COVD-19
March 16, 2020
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd.
July 10, 2018
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.